var data={"title":"Pamidronate: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Pamidronate: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6717?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=pamidronate-patient-drug-information\" class=\"drug drug_patient\">see &quot;Pamidronate: Patient drug information&quot;</a> and <a href=\"topic.htm?path=pamidronate-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Pamidronate: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205912\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Aredia;</li>\n      <li>Pamidronate Disodium;</li>\n      <li>Pamidronate Disodium Omega;</li>\n      <li>PMS-Pamidronate</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205952\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Bisphosphonate Derivative</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205914\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Single doses should not exceed 90 mg.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypercalcemia of malignancy:</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Moderate cancer-related hypercalcemia (corrected serum calcium: 12 to 13.5 mg/dL):</i> 60 to 90 mg, as a single dose over 2 to 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Severe cancer-related hypercalcemia (corrected serum calcium: &gt;13.5 mg/dL):</i> 90 mg, as a single dose over 2 to 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Re-treatment in patients who show an initial complete or partial response (allow at least 7 days to elapse prior to re-treatment):</i> May re-treat at the same dose if serum calcium does not return to normal or does not remain normal after initial treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Multiple myeloma, osteolytic bone lesions:</b> IV: 90 mg over 4 hours once monthly:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Lytic disease: American Society of Clinical Oncology (ASCO) guidelines:</i> 90 mg over at least 2 hours once every 3 to 4 weeks for 2 years; discontinue after 2 years in patients with responsive and/or stable disease; resume therapy with new-onset skeletal-related events (Kyle 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Newly-diagnosed, symptomatic (off-label dose):</i> 30 mg over 2.5 hours once monthly for at least 3 years (Gimsing 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Breast cancer, osteolytic bone metastases:</b> IV: 90 mg over 2 hours once every 3 to 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Paget's disease (moderate-to-severe):</b> IV: 30 mg over 4 hours once daily for 3 consecutive days (total dose = 90 mg); may re-treat at initial dose if clinically indicated</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hyperparathyroidism (off-label use): </b>IV: 15 to 90 mg as a single dose (Ammann 2003; Jansson 2004; Lu 2003); may be repeated every 1 to 2 months or when hypercalcemia recurs (Jansson 1991; Torregrosa 2003). The treatment period in clinical trials was up to 1 year (Torregrosa 2003).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prevention of androgen deprivation-induced osteoporosis (off-label use):</b> Males: IV: 60 mg over 2 hours once every 3 months (Smith 2001)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205915\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing. Begin at lower end of adult dosing range.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205916\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">Patients with serum creatinine &gt;3 mg/dL were excluded from clinical trials; there are only limited pharmacokinetic data in patients with CrCl &lt;30 mL/minute.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Manufacturer recommends the following guidelines:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Treatment of bone metastases: Use is not recommended in patients with severe renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal impairment in indications other than bone metastases: Use clinical judgment to determine if benefits outweigh potential risks.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Multiple myeloma: American Society of Clinical Oncology (ASCO) guidelines (Kyle 2007):</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe renal impairment (serum creatinine &gt;3 mg/dL <b>or</b> CrCl &lt;30 mL/minute) and extensive bone disease: 90 mg over 4 to 6 hours. However, a reduced initial dose should be considered if renal impairment was pre-existing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Albuminuria &gt;500 mg/24 hours (unexplained): Withhold dose until returns to baseline, then  recheck every 3 to 4 weeks; consider reinitiating at a dose not to exceed 90 mg every 4 weeks and with a longer infusion time of at least 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal toxicity:</b> In patients with bone metastases, treatment should be withheld for deterioration in renal function (increase of serum creatinine &ge;0.5 mg/dL in patients with normal baseline [serum creatinine &lt;1.4 mg/dL] or &ge;1 mg/dL in patients with abnormal baseline [serum creatinine &ge;1.4 mg/dL]). Resumption of therapy may be considered when serum creatinine returns to within 10% of baseline.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5697666\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Mild to moderate impairment: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Severe impairment: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205888\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous, as disodium: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 30 mg/10 mL (10 mL); 90 mg/10 mL (10 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous, as disodium [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 30 mg/10 mL (10 mL [DSC]); 6 mg/mL (10 mL); 90 mg/10 mL (10 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous, as disodium: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 30 mg (1 ea); 90 mg (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205873\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205892\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: Infusion rate varies by indication. Longer infusion times (&gt;2 hours) may reduce the risk for renal toxicity, especially in patients with preexisting renal insufficiency. The manufacturer recommends infusing over 2 to 24 hours for hypercalcemia of malignancy; over 2 hours for osteolytic bone lesions with metastatic breast cancer; and over 4 hours for Paget&rsquo;s disease and for osteolytic bone lesions with multiple myeloma. The ASCO guidelines for bisphosphonate use in multiple myeloma recommend infusing pamidronate over at least 2 hours; if therapy is withheld due to renal toxicity, infuse over at least 4 hours upon reintroduction of treatment after renal recovery (Kyle 2007).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49132758\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 3]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends double gloving, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed-system transfer devices (CSTDs) when compounding. Double gloving and a gown are required during administration (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205891\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;display:inline\">\n      <b>Hypercalcemia of malignancy:</b> Treatment of moderate or severe hypercalcemia associated with malignancy, with or without bone metastases, in conjunction with adequate hydration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Osteolytic bone metastases of breast cancer and osteolytic lesions of multiple myeloma:</b> Treatment of osteolytic bone metastases of breast cancer and osteolytic lesions of multiple myeloma in conjunction with standard antineoplastic therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Paget disease:</b> Treatment of patients with moderate to severe Paget disease of bone.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25469539\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Bone loss associated with androgen deprivation treatment in prostate cancer (prevention); Hyperparathyroidism; Osteogenesis imperfecta; Symptomatic bone metastases of thyroid cancer</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205962\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Aredia may be confused with Adriamycin</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pamidronate may be confused with papaverine</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205880\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Fatigue (osteolytic bone metastases: 32% to 40%; hypercalcemia of malignancy: &le;12%), headache (24% to 27%; Paget disease: &ge;10%), insomnia (osteolytic bone metastases: 25%; hypercalcemia of malignancy: &le;1%), anxiety (osteolytic bone metastases: 18%), pain (&le;13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hypophosphatemia (9% to 18%), hypokalemia (4% to 18%), hypocalcemia (1% to 17%), hypomagnesemia (4% to 12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (osteolytic bone metastases: 64%; hypercalcemia of malignancy: &le;18%; Paget disease: &ge;5%), vomiting (osteolytic bone metastases: 36% to 46%; hypercalcemia of malignancy: &le;4%), anorexia (osteolytic bone metastases: 31%; hypercalcemia of malignancy: &le;12%), abdominal pain (osteolytic bone metastases: 20% to 24%; hypercalcemia of malignancy: &le;1%), dyspepsia (osteolytic bone metastases: 18%; hypercalcemia of malignancy: &le;4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary tract infection (16% to 20%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Anemia (osteolytic bone metastases: 40% to 48%; hypercalcemia of malignancy: &le;6%), metastases (osteolytic bone metastases: 31%), granulocytopenia (osteolytic bone metastases: 20%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Infusion site reaction (hypercalcemia of malignancy: &le;18%; includes erythema, induration, pain, and swelling)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Myalgia (osteolytic bone metastases: 26%; hypercalcemia of malignancy: &le;1%), weakness (osteolytic bone metastases: 26%), ostealgia (5% to &ge;15%), arthralgia (osteolytic bone metastases: 11% to 15%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Increased serum creatinine (osteolytic bone metastases: 19%; mild)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Dyspnea (osteolytic bone metastases: 22% to 35%; other indications: &lt;1%), upper respiratory tract infection (osteolytic bone metastases: 32%; hypercalcemia of malignancy: &le;3%), cough (osteolytic bone metastases: 25%), sinusitis (osteolytic bone metastases: 16%), pleural effusion (osteolytic bone metastases: 15%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (18% to 39%; may be transient, includes temperature increase of &ge;1&deg; C within 24 to 48 hours after treatment; Paget disease, includes temperature increase of &ge;1&deg; C within 48 hours after treatment, transient: &le;21%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Atrial fibrillation (hypercalcemia of malignancy: &le;6%), hypertension (6%; Paget disease: &ge;10%), syncope (hypercalcemia of malignancy: &le;6%), tachycardia (hypercalcemia of malignancy: &le;6%), atrial flutter (hypercalcemia of malignancy: &le;1%), cardiac failure (hypercalcemia of malignancy: &le;1%), edema (hypercalcemia of malignancy: &le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Drowsiness (hypercalcemia of malignancy: &le;6%), psychosis (hypercalcemia of malignancy: &le;4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hypothyroidism (hypercalcemia of malignancy: &le;6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Constipation (hypercalcemia of malignancy: &le;6%), gastrointestinal hemorrhage (hypercalcemia of malignancy: &le;6%), diarrhea (hypercalcemia of malignancy: &le;1%), stomatitis (hypercalcemia of malignancy: &le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Uremia (hypercalcemia of malignancy: &le;4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Leukopenia (hypercalcemia of malignancy: &le;4%), neutropenia (hypercalcemia of malignancy: &le;1%), thrombocytopenia (hypercalcemia of malignancy: &le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Candidiasis (hypercalcemia of malignancy: &le;6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthropathy (Paget disease: &ge;5%), back pain (Paget disease: &ge;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Renal insufficiency (osteolytic bone metastases, patients with normal baseline serum creatinine: 8%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Rales (hypercalcemia of malignancy: &le;6%), rhinitis (hypercalcemia of malignancy: &le;6%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined: Endocrine &amp; metabolic: Hypervolemia (hypercalcemia of malignancy)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Adult respiratory distress syndrome, anaphylactic shock, angioedema, confusion, conjunctivitis, electrolyte disturbance, episcleritis, femur fracture (subtrochanteric and diaphyseal), flu-like symptoms, focal segmental glomerulosclerosis (including collapsing variant), glomerulopathy, hematuria, herpes simplex infection (reactivation), herpes zoster (reactivation), hyperkalemia, hypernatremia, hypersensitivity reaction, hypotension, interstitial pulmonary disease, iritis, local inflammation (orbital), malaise, mineral abnormalities, nephrotic syndrome, osteonecrosis (primarily of the jaw), paresthesia, pruritus, renal failure, renal tubular disease, scleritis, skin rash, tetany, uveitis, visual hallucination</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1% (Limited to important or life-threatening):</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening:</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205895\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to pamidronate, other bisphosphonates, or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205877\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone fractures: Atypical femur fractures (after minimal or no trauma) have been reported. The fractures include subtrochanteric femur (bone just below the hip joint) and diaphyseal femur (long segment of the thigh bone). Some patients experience prodromal pain weeks or months before the fracture occurs. It is unclear if bisphosphonate therapy is the cause for these fractures. Patients receiving long-term (&gt;3 to 5 years) bisphosphonate therapy may be at an increased risk. Consider discontinuing pamidronate in patients with a suspected femoral shaft fracture. Patients who present with thigh or groin pain in the absence of trauma should be evaluated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Musculoskeletal pain: Infrequently, severe (and occasionally debilitating) bone, joint, and/or muscle pain have been reported during bisphosphonate treatment. The onset of pain ranged from a single day to several months. Consider discontinuing therapy in patients who experience severe symptoms; symptoms usually resolve upon discontinuation. Some patients experienced recurrence when rechallenged with same drug or another bisphosphonate; avoid use in patients with a history of these symptoms in association with bisphosphonate therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Electrolyte abnormalities: Use has been associated with asymptomatic electrolyte abnormalities (including hypophosphatemia, hypokalemia, hypomagnesemia, and hypocalcemia). Rare cases of symptomatic hypocalcemia, including tetany,  have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Myelosuppression: Patients with preexisting anemia, leukopenia, or thrombocytopenia should be closely monitored during the first 2 weeks of treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Osteonecrosis of the jaw: Osteonecrosis of the jaw (ONJ), also referred to as medication-related osteonecrosis of the jaw (MRONJ), has been reported in patients receiving bisphosphonates. Known risk factors for MRONJ include invasive dental procedures (eg, tooth extraction, dental implants, boney surgery), cancer diagnosis, concomitant therapy (eg, chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, ill-fitting dentures, and comorbid disorders (anemia, coagulopathy, infection, preexisting dental or periodontal disease). Risk may increase with increased duration of bisphosphonate use and/or may be reported at a greater frequency based on tumor type (eg, advanced breast cancer, multiple myeloma). According to a position paper by the American Association of Maxillofacial Surgeons (AAOMS), MRONJ has been associated with bisphosphonates and other antiresorptive agents (denosumab), and antiangiogenic agents (eg, bevacizumab, sunitinib) used for the treatment of osteoporosis or malignancy; risk is significantly higher in cancer patients receiving antiresorptive therapy compared to patients receiving osteoporosis treatment (regardless of medication used or dosing schedule). MRONJ risk is also increased with monthly IV antiresorptive therapy compared to the minimal risk associated with oral bisphosphonate use, although risk appears to increase with oral bisphosphonates when duration of therapy exceeds 4 years. The AAOMS suggests that if medically permissible, initiation of IV bisphosphonates for cancer therapy should be delayed until optimal dental health is attained (if extractions are required, antiresorptive therapy should delayed until the extraction site has mucosalized or until after adequate osseous healing). Once IV bisphosphonate therapy is initiated for oncologic disease, procedures that involve direct osseous injury and placement of dental implants should be avoided. Patients developing ONJ during therapy should receive care by an oral surgeon (AAOMS [Ruggiero 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal deterioration: Single pamidronate doses should not exceed 90 mg. Initial or single doses have been associated with renal deterioration, progressing to renal failure and dialysis. Glomerulosclerosis (focal segmental) with or without nephrotic syndrome has also been reported. Longer infusion times (&gt;2 hours) may reduce the risk for renal toxicity, especially in patients with pre-existing renal insufficiency. Withhold pamidronate treatment (until renal function returns to baseline) in patients with evidence of renal deterioration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Breast cancer (metastatic): The American Society of Clinical Oncology (ASCO) updated guidelines on the role of bone-modifying agents (BMAs) in the prevention and treatment of skeletal-related events for metastatic breast cancer patients (Van Poznak, 2011). The guidelines recommend initiating a BMA (denosumab, pamidronate, zoledronic acid) in patients with metastatic breast cancer to the bone. There is currently no literature indicating the superiority of one particular BMA. Optimal duration is not yet defined; however, the guidelines recommend continuing therapy until substantial decline in patient&rsquo;s performance status. The ASCO guidelines are in alignment with prescribing information for dosing, renal dose adjustments, infusion times, prevention and management of osteonecrosis of the jaw, and monitoring of laboratory parameter recommendations. BMAs are not the first-line therapy for pain. BMAs are to be used as adjunctive therapy for cancer-related bone pain associated with bone metastasis, demonstrating a modest pain control benefit. BMAs should be used in conjunction with agents such as NSAIDS, opioid and nonopioid analgesics, corticosteroids, radiation/surgery, and interventional procedures.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypercalcemia of malignancy (HCM): Adequate hydration is required during treatment (urine output ~2 L/day); avoid overhydration, especially in patients with heart failure.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypoparathyroidism: Use caution with a history of thyroid surgery; patients may have relative hypoparathyroidism, predisposing them to pamidronate-related hypocalcemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Multiple myeloma: Patients with Bence-Jones proteinuria and dehydration should be adequately hydrated prior to therapy. The American Society of Clinical Oncology (ASCO) has also published guidelines on bisphosphonates use for prevention and treatment of bone disease in multiple myeloma (Kyle, 2007). Bisphosphonate (pamidronate or zoledronic acid) use is recommended in multiple myeloma patients with lytic bone destruction or compression spine fracture from osteopenia. Bisphosphonates may also be considered in patients with pain secondary to osteolytic disease, adjunct therapy to stabilize fractures or impending fractures, and for multiple myeloma patients with osteopenia but no radiographic evidence of lytic bone disease. Bisphosphonates are not recommended in patients with solitary plasmacytoma, smoldering (asymptomatic) or indolent myeloma, or monoclonal gammopathy of undetermined significance. The guidelines recommend monthly treatment for a period of 2 years. At that time, consider discontinuing in responsive and stable patients, and reinitiate if a new-onset skeletal-related event occurs. The ASCO guidelines are in alignment with the prescribing information for dosing, renal dose adjustments, infusion times, prevention and management of osteonecrosis of the jaw, and monitoring of laboratory parameter recommendations. According to the guidelines, in patients with extensive bone disease with existing severe renal disease (a serum creatinine &gt;3 mg/dL or CrCl &lt;30 mL/minute) pamidronate at a dose of 90 mg over 4 to 6 hours should be used (unless preexisting renal disease in which case a reduced initial dose should be considered). Monitor for albuminuria every 3 to 6 months; in patients with unexplained albuminuria &gt;500 mg/24 hours, withhold the dose until level returns to baseline, then recheck every 3 to 4 weeks. Pamidronate may be reinitiated at a dose not to exceed 90 mg every 4 weeks with a longer infusion time of at least 4 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Patients with serum creatinine &gt;3 mg/dL were not studied in clinical trials; limited data are available in patients with CrCl &lt;30 mL/minute. Evaluate serum creatinine prior to each treatment. For the treatment of bone metastases, use is not recommended in patients with severe renal impairment. With indications other than bone metastases, use clinical judgment to determine if benefits outweigh potential risks in patients with renal impairment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299814\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205882\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9736&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aminoglycosides: May enhance the hypocalcemic effect of Bisphosphonate Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Angiogenesis Inhibitors (Systemic): May enhance the adverse/toxic effect of Bisphosphonate Derivatives. Specifically, the risk for osteonecrosis of the jaw may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: Bisphosphonate Derivatives may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of Bisphosphonate Derivatives. Both an increased risk of gastrointestinal ulceration and an increased risk of nephrotoxicity are of concern.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Proton Pump Inhibitors: May diminish the therapeutic effect of Bisphosphonate Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thalidomide: May enhance the nephrotoxic effect of Pamidronate.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205884\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205897\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in animal reproduction studies. It is not known if bisphosphonates cross the placenta, but fetal exposure is expected (Djokanovic, 2008; Stathopoulos, 2011). Bisphosphonates are incorporated into the bone matrix and gradually released over time. The amount available in the systemic circulation varies by dose and duration of therapy. Theoretically, there may be a risk of fetal harm when pregnancy follows the completion of therapy; however, available data have not shown that exposure to bisphosphonates during pregnancy significantly increases the risk of adverse fetal events (Djokanovic, 2008; Levy, 2009; Stathopoulos, 2011). Until additional data is available, most sources recommend discontinuing bisphosphonate therapy in women of reproductive potential as early as possible prior to a planned pregnancy; use in premenopausal women should be reserved for special circumstances when rapid bone loss is occurring (Bhalla, 2010; Pereira, 2012;  Stathopoulos, 2011). Because hypocalcemia has been described following <i>in utero</i> bisphosphonate exposure, exposed infants should be monitored for hypocalcemia after birth (Djokanovic, 2008; Stathopoulos, 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14699812\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if pamidronate is present in breast milk. Pamidronate was not detected in the milk of a breastfeeding woman receiving pamidronate 30 mg IV monthly (therapy started ~6 months postpartum). Following the first infusion, milk was pumped and collected for 0 to 24 hours and 25 to 48 hours and each day pooled for analysis. Pamidronate readings were below the limit of quantification (&lt;0.4 micromole/L). During therapy, breast milk was pumped and discarded for the first 48 hours following each infusion prior to resuming breastfeeding. The infant was breastfed &gt;80% of the time; adverse events were not observed in the breastfed infant (Simonoski 2000). Monitoring the serum calcium concentrations of breastfed infants is recommended (Stathopoulos 2011). Due to the potential for serious adverse reactions in the breastfed infant, the manufacturer recommends a decision be made whether to discontinue breastfeeding or to discontinue the drug, taking into account the importance of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5697667\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Multiple myeloma or metastatic bone lesions from solid tumors or Paget&rsquo;s disease: Take adequate daily calcium and vitamin D supplement (if patient is not hypercalcemic). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205886\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Serum creatinine (prior to each treatment); serum electrolytes, including calcium, phosphate, magnesium, and potassium; CBC with differential; monitor for hypocalcemia for at least 2 weeks after therapy; dental exam and preventive dentistry prior to therapy for patients at risk of osteonecrosis, including all cancer patients; patients with pre-existing anemia, leukopenia, or thrombocytopenia should be closely monitored during the first 2 weeks of treatment; in addition, monitor urine albumin every 3 to 6 months in multiple myeloma patients </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205889\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">Calcium (total): Adults: 9 to 11 mg/dL (SI: 2.05 to 2.54 mmol/L), may slightly decrease with aging; Phosphorus: 2.5 to 4.5 mg/dL (SI: 0.81 to 1.45 mmol/L)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205876\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Nitrogen-containing bisphosphonate; inhibits bone resorption and decreases mineralization by disrupting osteoclast activity (Gralow 2009; Rogers 2011)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205894\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hypercalcemia of malignancy (HCM): Reduction of albumin-corrected serum calcium: Children: ~48 hours (Kerdudo 2005); Adults: &le;24 hours for decrease in albumin-corrected serum calcium; maximum effect: &le;7 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Paget disease: ~1 month for &ge;50% decrease in serum alkaline phosphatase</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Maximum effect: Hypercalcemia of malignancy: &le;7 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: HCM: 7 to 14 days; Paget disease: 1 to 372 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Poorly from the GI tract </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: 38% to 70% over 120 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Not metabolized </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 28 &plusmn; 7 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Biphasic; urine (30% to 62% as unchanged drug; lower in patients with renal dysfunction) within 120 hours </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323599\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Pamidronate Disodium Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6 mg/mL (10 mL): $33.65</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Pamidronate Disodium Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (1): $111.95</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">90 mg (1): $67.64</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205898\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Aminomux (AR, PY, UY, VE);</li>\n      <li>Aredia (AE, AT, BB, BE, BF, BG, BH, BJ, BM, BS, BZ, CH, CI, CL, CN, CO, CY, CZ, DE, DK, EE, EG, ES, ET, FI, FR, GB, GH, GM, GN, GR, GY, HK, HN, HR, HU, ID, IL, IN, IQ, IR, IT, JM, JO, JP, KE, KW, LB, LR, LU, LY, MA, ML, MR, MT, MU, MW, NE, NG, NL, NO, OM, PE, PH, PK, PL, PT, QA, RO, RU, SA, SC, SD, SE, SG, SI, SK, SL, SN, SR, SY, TH, TN, TR, TT, TW, TZ, UG, VN, YE, ZA, ZM, ZW);</li>\n      <li>Biodronate (LK);</li>\n      <li>Pamidria (LB);</li>\n      <li>Pamidrom (BR);</li>\n      <li>Pamidron (JO);</li>\n      <li>Pamisol (AU, MX, MY, NZ, SG, TW);</li>\n      <li>Pamitor (HR, TR);</li>\n      <li>Panolin (KR);</li>\n      <li>Panorin (KR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Dental Association Council on Scientific Affairs, &ldquo;Dental Management of Patients Receiving Oral Bisphosphonate Therapy,&rdquo; JADA, 2006, 137(8):1144-50. Available at http://jada.ada.org/article/S0002-8177(14)64960-6/pdf16873332</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ammann P, Herter-Clavel C, Lubrano A, Rizzoli R. A single bisphosphonate infusion is associated with improved functional capacity in elderly subjects with primary hyperparathyroidism. <i>Aging Clin Exp Res</i>. 2003;15(6):500-504.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pamidronate-drug-information/abstract-text/14959954/pubmed\" target=\"_blank\" id=\"14959954\">14959954</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aredia (pamidronate) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; May 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bamias A, Kastritis E, Bamia C, et al, &ldquo;Osteonecrosis of the Jaw in Cancer After Treatment With Bisphosphonates: Incidence and Risk Factors,&rdquo; <i>J Clin Oncol</i>, 2005, 23(34):8580-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pamidronate-drug-information/abstract-text/16314620/pubmed\" target=\"_blank\" id=\"16314620\">16314620</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bhalla AK, &quot;Management of Osteoporosis in a Pre-menopausal Woman,&quot; <i>Best Pract Res Clin Rheumatol</i>, 2010, 24(3):313-27.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pamidronate-drug-information/abstract-text/20534366/pubmed\" target=\"_blank\" id=\"20534366\">20534366</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Diamond TH, Winters J, Smith A, et al, &ldquo;The Antiosteoporotic Efficacy of Intravenous Pamidronate in Men With Prostate Carcinoma Receiving Combined Androgen Blockade: A Double Blind, Randomized, Placebo-Controlled Crossover Study,&rdquo; <i>Cancer</i>, 2001, 92(6):1444-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pamidronate-drug-information/abstract-text/11745221/pubmed\" target=\"_blank\" id=\"11745221\">11745221</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Djokanovic N, Klieger-Grossmann C, and Koren G, &quot;Does Treatment With Bisphosphonates Endanger the Human Pregnancy?&quot; <i>J Obstet Gynaecol Can</i>, 2008, 30(12):1146-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pamidronate-drug-information/abstract-text/19175968/pubmed\" target=\"_blank\" id=\"19175968\">19175968</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Durie BG, Katz M, and Crowley J, &ldquo;Osteonecrosis of the Jaw and Bisphosphonate,&rdquo; <i>N Engl J Med</i>, 2005, 353(1):99-102.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pamidronate-drug-information/abstract-text/16000365/pubmed\" target=\"_blank\" id=\"16000365\">16000365</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fitton A and McTavish D, &ldquo;Pamidronate: A Review of Its Pharmacological Properties and Therapeutic Efficacy in Resorptive Bone Disease,&rdquo; <i>Drugs</i>, 1991, 41(2):289-318.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pamidronate-drug-information/abstract-text/1709854/pubmed\" target=\"_blank\" id=\"1709854\">1709854</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    French AE, Kaplan N, Lishner M, et al, &ldquo;Taking Bisphosphonates During Pregnancy,&rdquo; <i>Can Fam Physician</i>, 2003, 49:1281-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pamidronate-drug-information/abstract-text/14594094/pubmed\" target=\"_blank\" id=\"14594094\">14594094</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gimsing P, Carlson K, Turesson I, et al, &ldquo;Effect of Pamidronate 30 mg Versus 90 mg on Physical Function in Patients With Newly Diagnosed Multiple Myeloma (Nordic Myeloma Study Group): A Double-Blind, Randomised Controlled Trial,&rdquo; <i>Lancet Oncol</i>, 2010, 11(10):973-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pamidronate-drug-information/abstract-text/20863761/pubmed\" target=\"_blank\" id=\"20863761\">20863761</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"9753709\"></a>Glorieux FH, Bishop NH, Plotkin H, et al, &ldquo;Cyclic Administration of Pamidronate in Children With Severe Osteogenesis Imperfecta,&rdquo; <i>N Engl J Med</i>, 1998, 339(14):947-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pamidronate-drug-information/abstract-text/9753709/pubmed\" target=\"_blank\" id=\"9753709\">9753709</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gralow JR, Biermann JS, Farooki A, et al, &ldquo;NCCN Task Force Report: Bone Health in Cancer Care,&rdquo; <i>J Natl Compr Canc Netw</i>, 2009, 7(Suppl 3):1-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pamidronate-drug-information/abstract-text/19555589/pubmed\" target=\"_blank\" id=\"19555589\">19555589</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &lt;800&gt; Hazardous Drugs&mdash;Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hellstein JW, Adler RA, Edwards B, et al, &quot;Managing the Care of Patients Receiving Antiresorptive Therapy for Prevention and Treatment of Osteoporosis: Executive Summary of Recommendations From the American Dental Association Council on Scientific Affairs,&quot; <i>J Am Dent Assoc</i>, 2011, 142(11):1243-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pamidronate-drug-information/abstract-text/22041409/pubmed\" target=\"_blank\" id=\"22041409\">22041409</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hellstein JW, Adler RA, Edwards B, et al, &quot;Managing the Care of Patients Receiving Antiresorptive Therapy for Prevention and Treatment of Osteoporosis: Recommendations From the American Dental Association Council on Scientific Affairs,&quot; 2011, Available at http://www.ada.org/sections/professionalResources/pdfs/topics_ARONJ_report.pdf. Accessed February 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hillner BE, Ingel JN, Chlebowski RT, et al, &ldquo;American Society of Clinical Oncology 2003 Update on the Role of Bisphosphonates and Bone Health Issues in Women With Breast Cancer,&rdquo; <i>J Clin Oncol</i>, 2003, 21(21):4042-57.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pamidronate-drug-information/abstract-text/12963702/pubmed\" target=\"_blank\" id=\"12963702\">12963702</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jansson S, Morgan E. Biochemical effects from treatment with bisphosphonate and surgery in patients with primary hyperparathyroidism. <i>World J Surg</i>. 2004;28(12):1293-1297.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pamidronate-drug-information/abstract-text/15517486/pubmed\" target=\"_blank\" id=\"15517486\">15517486</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jansson S, Tisell LE, Lindstedt G, Lundberg PA. Disodium pamidronate in the preoperative treatment of hypercalcemia in patients with primary hyperparathyroidism. <i>Surgery</i>. 1991;110(3):480-486.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pamidronate-drug-information/abstract-text/1845370/pubmed\" target=\"_blank\" id=\"1845370\">1845370</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kellihan MJ and Mangino PD, &ldquo;Pamidronate,&rdquo; <i>Ann Pharmacother</i>, 1992, 26(10):1262-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pamidronate-drug-information/abstract-text/1421653/pubmed\" target=\"_blank\" id=\"1421653\">1421653</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kerdudo C, Aerts I, Fattet S, et al. Hypercalcemia and childhood cancer: a 7-year experience. <i>J Pediatr Hematol Oncol</i>. 2005;27(1):23-27.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pamidronate-drug-information/abstract-text/15654274/pubmed\" target=\"_blank\" id=\"15654274\">15654274</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Khan AA, Morrison A, Hanley DA, et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. <i>J Bone Miner Res.</i> 2015; 30(1):3-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pamidronate-drug-information/abstract-text/25414052/pubmed\" target=\"_blank\" id=\"25414052\">25414052</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kyle RA, Yee GC, Somerfield MR, et al, &ldquo;American Society of Clinical Oncology 2007 Clinical Practice Guideline Update on the Role of Bisphosphonates in Multiple Myeloma,&rdquo; <i>J Clin Oncol</i>, 2007, 25(17):2464-72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pamidronate-drug-information/abstract-text/17515569/pubmed\" target=\"_blank\" id=\"17515569\">17515569</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Levy S, Fayez I, Taguchi N, et al, &quot;Pregnancy Outcome Following <i>in utero</i> Exposure to Bisphosphonates,&quot; <i>Bone</i>, 2009, 44(3):428-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pamidronate-drug-information/abstract-text/19059370/pubmed\" target=\"_blank\" id=\"19059370\">19059370</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lteif AN and Zimmerman D, &ldquo;Bisphosphonates for Treatment of Childhood Hypercalcemia,&rdquo; <i>Pediatrics</i>, 1998, 102(4 Pt 1):990-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pamidronate-drug-information/abstract-text/9755274/pubmed\" target=\"_blank\" id=\"9755274\">9755274</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lu KC, Yeung LK, Lin SH, Lin YF, Chu P. Acute effect of pamidronate on PTH secretion in postmenopausal hemodialysis patients with secondary hyperparathyroidism. <i>Am J Kidney Dis</i>. 2003;42(6):1221-1227.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pamidronate-drug-information/abstract-text/14655194/pubmed\" target=\"_blank\" id=\"14655194\">14655194</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Maerevoet M, Martin C, and Duck L, &ldquo;Osteonecrosis of the Jaw and Bisphosphonates,&rdquo; <i>N Engl J Med</i>, 2005, 353(1):99-102.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pamidronate-drug-information/abstract-text/16003838/pubmed\" target=\"_blank\" id=\"16003838\">16003838</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Major P, Lortholary A, Hon J, et al, &quot;Zoledronic Acid Is Superior to Pamidronate in the Treatment of Hypercalcemia of Malignancy: A Pooled Analysis of Two Randomized, Controlled Clinical Trials,&quot; <i>J Clin Oncol</i>, 2001, 19(2):558-67.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pamidronate-drug-information/abstract-text/11208851/pubmed\" target=\"_blank\" id=\"11208851\">11208851</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McMahon RE, Bouquot JE, Glueck CJ, et al, &ldquo;Osteonecrosis: A Multifactorial Etiology,&rdquo; <i>J Oral Maxillofac Surg</i>, 2004, 62(7):904-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pamidronate-drug-information/abstract-text/15244000/pubmed\" target=\"_blank\" id=\"15244000\">15244000</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pamidronate Disodium [package insert]. Bedford, OH: Bedford Laboratories; October 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pamidronate Disodium [package insert]. Lake Forest, IL: Hospira, Inc; September 2009.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pamidronate disodium [prescribing information].Georgetown, IN: Areva Pharmaceuticals Inc.; July 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pereira RM, Carvalho JF, Paula AP, et al, &quot;Guidelines for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis,&quot; <i>Rev Bras Reumatol</i>, 2012, 52(4):580-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pamidronate-drug-information/abstract-text/22885424/pubmed\" target=\"_blank\" id=\"22885424\">22885424</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ralston SH, Gallacher SJ, Patel U, et al, &ldquo;Cancer-Associated Hypercalcemia: Morbidity and Mortality, Clinical Experience in 126 Treated Patients,&rdquo; <i>Ann Intern Med</i>, 1990, 112(7):499-504.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pamidronate-drug-information/abstract-text/2138442/pubmed\" target=\"_blank\" id=\"2138442\">2138442</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rauch F and Glorieux FH, &ldquo;Osteogenesis Imperfecta,&rdquo; <i>Lancet</i>, 2004, 363(9418):1377-85.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pamidronate-drug-information/abstract-text/15110498/pubmed\" target=\"_blank\" id=\"15110498\">15110498</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rogers MJ, Crockett JC, Coxon FP, et al, &ldquo;Biochemical and Molecular Mechanisms of Action of Bisphosphonates,&rdquo; <i>Bone</i>, 2011, 49(1):34-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pamidronate-drug-information/abstract-text/21111853/pubmed\" target=\"_blank\" id=\"21111853\">21111853</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ruggiero SL, Dodson TB, Fantasia J, et al; American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. <i>J Oral Maxillofac Surg</i>. 2014;72(10):1938-1956. doi: 10.1016/j.joms.2014.04.031.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pamidronate-drug-information/abstract-text/25234529/pubmed\" target=\"_blank\" id=\"25234529\">25234529</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ruggiero S, Gralow J, Marx RE, et al, &quot;Practical Guidelines for the Prevention, Diagnosis, and Treatment of Osteonecrosis of the Jaw in Patients With Cancer,&quot; <i>J Clin Oncol</i>, 2006, 2(1):7-14.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Siminoski K, Fitzgerald AA, Flesch G, et al, &quot;Intravenous Pamidronate for Treatment of Reflex Sympathetic Dystrophy During Breast Feeding,&quot;<i>J Bone Miner Res</i>, 2000, 15(10):2052-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pamidronate-drug-information/abstract-text/11028460/pubmed\" target=\"_blank\" id=\"11028460\">11028460</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"11575286\"></a>Smith MR, McGovern FJ, Zietman AL, et al, &ldquo;Pamidronate to Prevent Bone Loss During Androgen-Deprivation Therapy For Prostate Cancer,&rdquo; <i>N Engl J Med,</i> 2001, 345(13):948-55.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pamidronate-drug-information/abstract-text/11575286/pubmed\" target=\"_blank\" id=\"11575286\">11575286</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stathopoulos IP, Liakou CG, Katsalira A, et al, &quot;The Use of Bisphosphonates in Women Prior to or During Pregnancy and Lactation,&quot; <i>Hormones (Athens)</i>, 2011, 10(4):280-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pamidronate-drug-information/abstract-text/22281884/pubmed\" target=\"_blank\" id=\"22281884\">22281884</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Steelman J and Zeitler P, &ldquo;Treatment of Symptomatic Pediatric Osteoporosis With Cyclic Single-Day Intravenous Pamidronate Infusions,,&rdquo; <i>J Pediatr</i>, 2003, 142(4):417-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pamidronate-drug-information/abstract-text/12712060/pubmed\" target=\"_blank\" id=\"12712060\">12712060</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tarassoff P and Csermak K, &ldquo;Avascular Necrosis of the Jaws: Risk Factors in Metastatic Cancer Patients,&rdquo; <i>J Oral Maxillofac Surg</i>, 2003, 61(10):1238-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pamidronate-drug-information/abstract-text/14586868/pubmed\" target=\"_blank\" id=\"14586868\">14586868</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Torregrosa JV, Moreno A, Mas M, Ybarra J, Fuster D. Usefulness of pamidronate in severe secondary hyperparathyroidism in patients undergoing hemodialysis. <i>Kidney Int Suppl</i>. 2003;(85):S88-S90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pamidronate-drug-information/abstract-text/12753274/pubmed\" target=\"_blank\" id=\"12753274\">12753274</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 3, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"11401309\"></a>Vitale G, Fonderico F, Martignetti A, et al, &ldquo;Pamidronate Improves the Quality of Life and Induces Clinical Remission of Bone Metastases in Patients With Thyroid Cancer,&rdquo; <i>Br J Cancer</i>, 2001, 84(12):1586-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pamidronate-drug-information/abstract-text/11401309/pubmed\" target=\"_blank\" id=\"11401309\">11401309</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Van Poznak CH, Temin S, Yee GC, et al, &ldquo;American Society of Clinical Oncology Executive Summary of the Clinical Practice Guideline Update on the Role of Bone-Modifying Agents in Metastatic Breast Cancer,&rdquo; <i>J Clin Oncol</i>, 2011, 29(9):1221-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pamidronate-drug-information/abstract-text/21343561/pubmed\" target=\"_blank\" id=\"21343561\">21343561</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9736 Version 164.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F205912\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F205952\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F205914\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F205915\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F205916\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F5697666\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F205888\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F205873\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F205892\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49132758\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F205891\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25469539\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F205962\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F205880\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F205895\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F205877\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299814\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F205882\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F205884\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F205897\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F14699812\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F5697667\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F205886\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F205889\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F205876\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F205894\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323599\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F205898\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9736|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=pamidronate-patient-drug-information\" class=\"drug drug_patient\">Pamidronate: Patient drug information</a></li><li><a href=\"topic.htm?path=pamidronate-pediatric-drug-information\" class=\"drug drug_pediatric\">Pamidronate: Pediatric drug information</a></li></ul></div></div>","javascript":null}